The Russian invasion of Ukraine is already dealing a blow to financial markets and the worldwide economy. Global supply chains and growth had been broadly recovering from the pandemic, but now all that’s in doubt, given the stricter sanctions and other punitive measures against Russia that are in the offing.
The war has introduced a lot of unknowns for global trade, financial markets, multinational corporations and national economies, including the U.S. economy.
This new war at the eastern edge of Europe cuts into food and energy supplies, which means higher prices, and generates risk, which is expensive.
The Russian invasion of Ukraine is likely to snarl global trade even further, while sending gas prices soaring and stock markets into correction territory, analysts say.
An invasion of Ukraine, which has been dubbed “the breadbasket of Europe” because it is a major producer of wheat, barley, corn and rye that is consumed largely by Europe, may upset supply chains even further.
This could also affect countries in the Middle East and Africa that also import Ukrainian wheat and corn. Ukraine is also China’s top supplier of corn.
However harsh the effects, the immediate impact will be nowhere near as devastating as the sudden economic shutdowns first caused by the coronavirus in 2020. Russia is a transcontinental behemoth with 146 million people and a huge nuclear arsenal, as well as a key supplier of the oil, gas and raw materials that keep the world’s factories running. But unlike China, which is a manufacturing powerhouse and intimately woven into intricate supply chains, Russia is a minor player in the global economy.
Reference:
https://www.nytimes.com/2022/02/21/business/economy/ukraine-russia-economy.html/
https://nypost.com/2022/02/24/global-trade-to-suffer-more-after-russia-invasion-of-ukraine/
In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.
The global pharmaceutical fine chemicals sector is undergoing a profound transformation, with India emerging as a central growth engine amid sweeping changes in supply chain strategies and regulatory priorities. As drug makers and contract manufacturers adapt to stricter oversight and evolving sourcing preferences, the industry’s focus is shifting rapidly from cost efficiency to compliance, localisation and technical sophistication.
Stakeholders are being encouraged to weigh in on the European Chemicals Agency (ECHA) 60-day public consultation period related to a planned ban on per-and-polyfluoroalkyl (PFAS) substances, also known as forever chemicals.
We’re pleased to share an important milestone in our sustainability journey.
ExSyn has been awarded the EcoVadis Platinum Medal, placing us among the top 1% of companies globally evaluated for environmental, social and ethical performance.
While fears around a complete shutdown of the Strait of Hormuz primarily raise concerns around oil prices and energy security, recent history shows that even partial disruptions or security threats along key sea routes can quickly spill over into freight inflation, longer transit times and working capital stress for exporters and importers.
The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to zero.
As we approach the close of this year, we at ExSyn would like to extend our heartfelt gratitude for your trust, collaboration, and continued support. Your confidence in our products and services has been the driving force behind our growth and success.
The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases.
Products containing titanium dioxide in the EU are no longer required to carry warnings about cancer risk, after the European Chemicals Agency (Echa) revoked its classification as a suspected carcinogen. The move follows a June 2025 decision by the Court of Justice of the European Union and means that safety data sheets, labelling and packaging requirements for titanium dioxide have been relaxed across industries including paints, pharmaceuticals, cosmetics and food.